跳至主要内容
临床试验/NCT00574574
NCT00574574已完成不适用

Biological Effects of an Anthocyanin Rich Dietary Supplement on Skin Ageing and Markers of Inflammation in Post-Menopausal Women

University of East Anglia1 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2007年8月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
62
试验地点
1
主要终点
Measure: Evidence of significant differences in skin health parameters, between active treatment and placebo supplementation period.

研究概览

简要总结

The purpose of this study is to determine whether short-term exposure to a compound found in some fruits and vegetables (anthocyanin), is effective in improving skin health and reducing the levels of various markers of cardiovascular disease risk. A range of skin health parameters are being studied and volunteers are also providing skin biopsy, urine and blood samples. 62 postmenopausal women have been recruited for this study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
— 至 70 Years(Child, Adult, Older Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •Upper age limit of 70 years
  • •Minimum of 1 year since last menstruation
  • •Not taking Hormone Replacement Therapy (HRT), and not having taken HRT for a minimum of 6 months prior to commencement
  • •Having no significant past or present medical history of: inflammatory conditions (including eczema, asthma, hay fever, IBS, crohn's disease and arthritis), diabetes, hepatic, renal, cardiac, pulmonary, digestive, haematological, neurological, thyroidal or psychiatric disease.
  • •Agreeing to restrict dietary intake of anthocyanin containing foodstuffs and also other foodstuffs considered to be cardio-protective i.e. red wine, total alcohol, oily fish, dark chocolate, tea and coffee.
  • •Agreeing to maintain existing cosmetic and beauty regime, and avoid 'tanning' (either naturally or synthetically) of the specific sites of skin function measurement during the study.
  • •BMI 20-32 kg/m2
  • •Successful biochemical, haematological and urinalysis assessment

排除标准

  • •allergy / sensitivity to local anaesthetic i.e. Xylocaïne
  • •Regular use of aspirin, or other anti-inflammatory pain relief medication, as prescribed by a doctor. [If subjects are regular self prescribed aspirin users and are willing to give up aspirin 2 months prior to the study and for the duration of the study they can be included.]
  • •Taking other counter indicative medication e.g. steroidal medication during the trial, or within 1 month of the trial beginning.
  • •Taking food / dietary supplements e.g. vitamins, minerals, fish oils, plant oils, isoflavones, soy products, carotenoids during the trial (unless prepared to cease intake during, and 1 month preceding the trial).
  • •Those on therapeutic diets or following weight-loss diet.
  • •Current smoker, or smoker in the past year
  • •Having vaccinations or antibiotics within 3 months of start of trial, and those with vaccinations scheduled for during the trial
  • •Parallel participation in another research project which involves dietary intervention and/or sampling of biological fluids/material
  • •Participation in another research project within the last four months unless the total amount of combined blood from both studies will not exceed 470ml.
  • •Those intending to travel during the study to locations where a change in skin colour may be anticipated
  • •Subjects intending to deliberately "sunbathe", use tanning solariums or tanning creams on body sites used for assessment.
  • •Assessed from the clinical screening
  • •abnormal renal function (Na >145mmol/L, K >5.0mmol/L, Urea >7.1mmol/L, Albumin >50g/L, Creatinine >125μmol/L, Total bilirubin >22μmol/L), or liver function (ALP >126 IU/L, ALT >50 IU/L), lipid profile (Total cholesterol > 6.5 mmol/l, TAG >3.0 mmol/l, HDL>2.0 mmol/l), anaemia (Haemoglobin <11.5g/dL), fasting glucose (> 6.1 mmol/l) or measurements considered to be counter indicative of the trial outcome measures.
  • •Untreated hypertension (>160/90mmHg) or hypotension (90/50mmHg or 95/50mmHg if symptomatic)
  • •BMI <19.5 or >32.5

研究组 & 干预措施

1

Experimental

500mg/d of anthocyanin, contained in 4 X 250mg capsules (125mg anthocyanin/ capsule). 2 capsules to be taken with food, twice per day (n=4 in total).

干预措施: anthocyanin (Dietary Supplement)

2

Placebo Comparator

500mg/d of placebo control containing no anthocyanin, 2 X 250mg capsules to be taken with food, twice per day (n=4, 250mg capsules in total / d).

干预措施: anthocyanin (Dietary Supplement)

结局指标

主要结局

Measure: Evidence of significant differences in skin health parameters, between active treatment and placebo supplementation period.

时间窗: 12 Weeks

次要结局

  • Measure: Evidence of significant differences in inflammatory status, between active treatment and placebo supplementation period.(12 Weeks)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验